If you have been reading about Research chemical and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common for reference-grade material. |
| Solubility | Low in water | Dissolves in DMSO and some organic solvents. |
| Typical storage | -20 °C, desiccated | Protect from light and moisture. |
| Analytical method | LC-MS/MS | Used for trace detection in biological matrices. |
| Purity assessment | HPLC with UV detection | Often combined with NMR and mass spectrometry. |
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Fuel savings: According to the GITI, for every 10% of under-inflation on each tire on a vehicle, a 1% reduction in fuel economy will occur. In the United States alone, the Department of Transportation estimates that under inflated tires waste 2 billion US gallons (7,600,000 m3) of fuel each year. Extended tire life: Under inflated tires are the number one cause of tire failure and contribute to tire disintegration, heat buildup, ply separation and sidewall/casing breakdowns. Further, a difference of 10 pounds per square inch (69 kPa; 0.69 bar) in pressure on a set of duals literally drags the lower pressured tire 2.5 metres per kilometre (13 feet per mile). Moreover, running a tire even briefly on inadequate pressure breaks down the casing and prevents the ability to retread. Not all sudden tire failures are caused by under-inflation. Structural damages caused, for example, by hitting sharp curbs or potholes, can also lead to sudden tire failures, even a certain time after the damaging incident. These cannot be proactively detected by any TPMS. Improved safety: Under-inflated tires lead to tread separation and tire failure, resulting in 40,000 accidents, 33,000 injuries and over 650 deaths per year. Properly inflated tires provide greater stability, handling, and braking efficiency. Environmental efficiency: Under-inflated tires, as estimated by the US Department of Transportation, release over 26 billion kilograms (57.5 billion pounds) of unnecessary carbon-monoxide pollutants into the atmosphere each year in the United States alone.
Some of these cells (for example, LLC MK2, 4647 and HEK 293) do not express a protease that processes fusion protein F0 of Sendai virus; therefore, they produce non-infectious virions. Type 1 IFN inhibits the SeV production in normal human respiratory cells, but fails of doing it in human cells that originates from variable malignancies such as U937, Namalwa, and A549. Variable cell cultures obtained from tumors have different sensitivity to SeV, and can also produce the virus in different quantities. There are multiple factors that are responsible for this variability. For example, an inverse correlation was observed between cells sensitivity to SeV infection and constitutive mRNA expression levels of TLR 3 and TLR 7 in primary cultures of prostate cancer. Thus, defective TLR-activated IFN signaling is one of these factors.
=== Early studies === Fourteen years after the first publication on its detection in 1973, 12-HHT was reported to stimulate fetal bovine aortic and human umbilical vein endothelial cells to metabolize arachidonic acid to prostaglandin I2 (PGI2 or prostacyclin), a powerful inhibitor of platelet activation and stimulator of vasodilation (see Prostacyclin synthase). 12-HHT did not, however, alter arachidonic acid metabolism in human platelets. Shortly thereafter, 12-HHT was reported to inhibit the chemotaxis-blocking effect of a human monocyte-derived factor on human monocytes. 12-Oxo-HT, the immediate metabolite of 12-HHT, was reported to stimulate the chemotasis of human neutrophils and to inhibit platelet aggregation responses to various agents by stimulating platelets to raise their levels of cyclic adenosine monophosphate (cAMP), an intracellular signal that serves broadly to inhibit platelet activation. These studies were largely overlooked; in 1998 and 2007 publications, for example, 12-HHT was regarded as either inactive or without significant biological activity. Nonetheless, this early work suggested that 12-HHT may serve as a contributor to monocyte- and neutrophil-based inflammatory responses, and that 12-oxo-HT may serve as a counterpoise to platelet aggregation responses elicited or promoted by TXA2.
In order to avoid the stigma of a restaurant chain, Smashburger crafts local burgers for each city where it is located and markets them extensively. These burgers are designed after consulting with distributors for the kinds of ingredients that are most shipped to a particular city or geographic area. For instance, Smashburger's Colorado locations serve burgers with roasted green chiles, while locations in Miami serve burgers with grilled chorizo. In Minneapolis, the chain has a double-cheese, double-onion variety evoking Scandinavian and Germanic cuisine. Its Oklahoma variety features locally popular fried pickles, while Boston locations serve a burger with onions and a cranberry chutney supplied locally by Ocean Spray. The burgers tend to be original creations as opposed to duplicating local flavors; in the case of Minneapolis the chain deliberately avoided selling a burger that would resemble the locally renowned Jucy Lucy. There are exceptions, such as in Kalamazoo and Grand Rapids restaurants, where the local burger is topped with olives, a tradition that had once been locally popular. The restaurant attracted criticism from health experts for the unhealthiness of some of its menu offerings. A large BBQ Bacon and Cheddar Smashburger has 1,050 calories, while a Chocolate Oreo Shake has 950 calories. Initially, the restaurant made only larger burgers and marketed large servings as a value add, but as it grew it began to offer different sizes to appeal to a larger audience.
The principal process parameters are grinding gas pressure, feed rate, and the ratio between them; increasing pressure or decreasing feed rate generally shifts the particle size distribution finer. Because the expanding gas cools as it leaves the nozzles, jet milling imparts much less thermal stress than mechanical mills, allowing micronization of thermolabile and low-melting actives. However, the high specific energy input can induce surface amorphization, lattice strain, and changes in surface energy that affect downstream processability and stability. For highly potent compounds — such as steroidal hormones, cytotoxic oncology actives, and antibody–drug conjugate payloads — jet mills are operated inside containment isolators meeting occupational exposure limits in the nanogram-per-cubic-metre range. Methods like crushing and cutting are also used for reducing particle diameter, but produce more rough particles compared to the two previous techniques (and are therefore the early stages of the micronization process). Crushing employs hammer-like tools to break the solid into smaller particles by means of impact. Cutting uses sharp blades to cut the rough solid pieces into smaller ones. In pharmaceutical jet milling, the specific energy (energy input per unit mass of feed) is the principal factor governing the resulting particle size and is used as the basis for scaling the process from laboratory to commercial manufacture.
Sources: en.wikipedia.org
American Diabetes Association IDF Diabetes Atlas National Diabetes Education Program ADA's Standards of Medical Care in Diabetes 2019 Polonsky KS (October 2012). "The past 200 years in diabetes". The New England Journal of Medicine. 367 (14): 1332–1340. doi:10.1056/NEJMra1110560. PMID 23034021. S2CID 9456681. "Diabetes". MedlinePlus. U.S. National Library of Medicine.
== Bibliography == Cécile Allegri, Claire Brosse, Federico Oldenburg and Hervé Robert, La Pomme de terre, saveurs méditerranéennes, Éditions du Bottin Gourmand, coll. « Les essentiels du goût », 2003, 99 p. (ISBN 2-913306-61-6). Joseph Bonjean, Monographie de la pomme de terre envisagée dans ses rapports agricoles, scientifiques et industriels et comprenant l'histoire générale de la maladie des pommes de terre en 1845, Paris, Germer Baillière, 1846, 306 p. Collective, La Pomme de terre. Histoire et recettes gourmandes, Grenoble, Glénat, 2009, 160 p. (ISBN 2-7234-7319-8). Collective, La Pomme de terre, un tour du Monde en 200 recettes, Geneva, United Nations, 2008, 360 p. (ISBN 92-1-200373-7). Lucienne Desnoues, Toute la pomme de terre, Paris, Mercure de France, 1978, 302 p. Qu Dongyu et Xie Kaiyun, How the Chinese Eat Potatoes, Singapour, World Scientific Publishing Company, 2009, 432 p. (ISBN 981-283-291-2). Jean Ferniot (pref. Joël Robuchon), Chère pomme de terre, First, 1996, 301 p. (ISBN 978-2-87691-327-1). Martine Jolly, Merci M. Parmentier, ou La gloire de la pomme de terre en 200 recettes, Robert Laffont, 1985, 224 p. (ISBN 2-221-04653-6). Mme Mérigot, La Cuisinière républicaine, qui enseigne la manière simple d'accommoder les pommes de terre; avec quelques avis sur les soins nécessaires pour les conserver Archived July 12, 2023, at the Wayback Machine, Paris, Chez Mérigot jeune, 1794–1795, 42 p. C. Monteros, J. Jiménez, Gavilanes, La Magia de la Papa Nativa. Recetario Gastronómico, Quito, INIAP, 2006, 71 p.
=== Wellcome Superstore === The first Wellcome Superstore was opened in 2000 and currently it has 31 superstores, spread across Hong Kong. They stock a greater variety of products, tailored to local demand.
== SI == si – (s) Sinhala language (ISO 639-1 code) Si – (s) Silicon SI (s) Slovenia (ISO 3166 and FIPS 10-4 country code digram) (i) Socialist International Sports Illustrated Système International (French, International System of Units) SIA – (s) Singapore Airlines (ICAO code) SIA – (i) Survivors of Incest Anonymous SIAM – (i) Society for Industrial and Applied Mathematics SIC – (a) Standard Industrial Classification SICS – (a/i) Swedish Institute of Computer Science SIDS – (a) Sudden infant death syndrome SIDU – (i) select, insert, delete, update. See Create, read, update and delete SIF – (i) Selective Identification Feature SIFF – (i) Successor IFF SIG (i) Schweizerische Industrie Gesellschaft (German, "Swiss Industry Company"). See also SIG Sauer, a firearms manufacturer spun off from the aforementioned company in 2000.
Following Bogdanov's lead, Vladimir Shamov and Sergei Yudin in the USSR pioneered the transfusion of cadaveric blood from recently deceased donors. Yudin performed such a transfusion successfully for the first time on March 23, 1930, and reported his first seven clinical transfusions with cadaveric blood at the Fourth Congress of Ukrainian Surgeons at Kharkiv in September. However, this method was never used widely, even in the Soviet Union. Nevertheless, the Soviet Union was the first to establish a network of facilities to collect and store blood for use in transfusions at hospitals.
Sources: en.wikipedia.org
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.
Reference material is usually kept cold, dry, and protected from light. Frozen aliquots reduce repeated freeze-thaw cycles.
No approved pharmaceutical product exists, so manufacturing and quality controls are not standardized. Products may contain different compounds or impurities.
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.